U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Ovarian Carcinoma

MedGen UID:
78865
•Concept ID:
C0278689
•
Neoplastic Process
Synonyms: Recurrent Carcinoma of Ovary; Recurrent Carcinoma of the Ovary; Recurrent Epithelial Cancer of Ovary; Recurrent Epithelial Cancer of the Ovary; Recurrent Ovarian Cancer; Recurrent ovarian cancer; Recurrent Ovarian Epithelial Cancer; Relapsed Carcinoma of Ovary; Relapsed Carcinoma of the Ovary; Relapsed Epithelial Cancer of Ovary; Relapsed Epithelial Cancer of the Ovary; Relapsed ovarian cancer; Relapsed Ovarian Carcinoma; Relapsed Ovarian Epithelial Cancer
SNOMED CT: Relapsed ovarian cancer (461371000124103); Recurrent ovarian cancer (461371000124103)

Definition

The reemergence of ovarian carcinoma after a period of remission. [from NCI]

Professional guidelines

PubMed

Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Wolford JE, Bai J, Moore KN, Kristeleit R, Monk BJ, Tewari KS
Gynecol Oncol 2020 May;157(2):500-507. Epub 2020 Mar 13 doi: 10.1016/j.ygyno.2020.02.030. PMID: 32173049Free PMC Article
Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP, Schilder RJ
Semin Oncol 2009 Apr;36(2):112-25. doi: 10.1053/j.seminoncol.2008.12.003. PMID: 19332246
Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy.
González-Martín A; GEICO Group
Int J Gynecol Cancer 2005 Nov-Dec;15 Suppl 3:241-6. doi: 10.1111/j.1525-1438.2005.00436.x. PMID: 16343239

Recent clinical studies

Etiology

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L
J Clin Oncol 2022 Aug 1;40(22):2436-2446. Epub 2022 Apr 11 doi: 10.1200/JCO.21.01511. PMID: 35404684
Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL, Chi DS, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, O'Cearbhaill RE, Abu-Rustum NR, Leitao MM Jr
Gynecol Oncol 2021 Aug;162(2):345-352. Epub 2021 May 25 doi: 10.1016/j.ygyno.2021.05.015. PMID: 34045053Free PMC Article
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL
Lancet Oncol 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. PMID: 32359490Free PMC Article
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP, Schilder RJ
Semin Oncol 2009 Apr;36(2):112-25. doi: 10.1053/j.seminoncol.2008.12.003. PMID: 19332246

Diagnosis

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L
J Clin Oncol 2022 Aug 1;40(22):2436-2446. Epub 2022 Apr 11 doi: 10.1200/JCO.21.01511. PMID: 35404684
Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL, Chi DS, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, O'Cearbhaill RE, Abu-Rustum NR, Leitao MM Jr
Gynecol Oncol 2021 Aug;162(2):345-352. Epub 2021 May 25 doi: 10.1016/j.ygyno.2021.05.015. PMID: 34045053Free PMC Article
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL
Lancet Oncol 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. PMID: 32359490Free PMC Article
When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M, Harter P, Heitz F, du Bois A
Clin Oncol (R Coll Radiol) 2018 Aug;30(8):493-497. Epub 2018 May 7 doi: 10.1016/j.clon.2018.04.006. PMID: 29743148
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article

Therapy

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L
J Clin Oncol 2022 Aug 1;40(22):2436-2446. Epub 2022 Apr 11 doi: 10.1200/JCO.21.01511. PMID: 35404684
Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL, Chi DS, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, O'Cearbhaill RE, Abu-Rustum NR, Leitao MM Jr
Gynecol Oncol 2021 Aug;162(2):345-352. Epub 2021 May 25 doi: 10.1016/j.ygyno.2021.05.015. PMID: 34045053Free PMC Article
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL
Lancet Oncol 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. PMID: 32359490Free PMC Article
When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M, Harter P, Heitz F, du Bois A
Clin Oncol (R Coll Radiol) 2018 Aug;30(8):493-497. Epub 2018 May 7 doi: 10.1016/j.clon.2018.04.006. PMID: 29743148
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article

Prognosis

Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M, Mogi K, Kitami K, Uno K, Iyoshi S, Tano S, Fujimoto H, Miyamoto E, Yoshikawa N, Emoto R, Matsui S, Kajiyama H
Int J Clin Oncol 2022 Oct;27(10):1660-1668. Epub 2022 Jul 30 doi: 10.1007/s10147-022-02214-9. PMID: 35906336
When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M, Harter P, Heitz F, du Bois A
Clin Oncol (R Coll Radiol) 2018 Aug;30(8):493-497. Epub 2018 May 7 doi: 10.1016/j.clon.2018.04.006. PMID: 29743148
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP, Schilder RJ
Semin Oncol 2009 Apr;36(2):112-25. doi: 10.1053/j.seminoncol.2008.12.003. PMID: 19332246
Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
Kose MF, Meydanli MM, Tulunay G
Expert Rev Anticancer Ther 2006 Mar;6(3):437-43. doi: 10.1586/14737140.6.3.437. PMID: 16503860

Clinical prediction guides

Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M, Mogi K, Kitami K, Uno K, Iyoshi S, Tano S, Fujimoto H, Miyamoto E, Yoshikawa N, Emoto R, Matsui S, Kajiyama H
Int J Clin Oncol 2022 Oct;27(10):1660-1668. Epub 2022 Jul 30 doi: 10.1007/s10147-022-02214-9. PMID: 35906336
When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M, Harter P, Heitz F, du Bois A
Clin Oncol (R Coll Radiol) 2018 Aug;30(8):493-497. Epub 2018 May 7 doi: 10.1016/j.clon.2018.04.006. PMID: 29743148
Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis.
Limei Z, Yong C, Yan X, Shuai T, Jiangyan X, Zhiqing L
Int J Gynecol Cancer 2013 May;23(4):598-607. doi: 10.1097/IGC.0b013e31828a183c. PMID: 23502451
Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy.
González-Martín A; GEICO Group
Int J Gynecol Cancer 2005 Nov-Dec;15 Suppl 3:241-6. doi: 10.1111/j.1525-1438.2005.00436.x. PMID: 16343239
Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
Zang RY, Yang WT, Shi DR, Xing Y, Cai SM
J Surg Oncol 2005 Jul 1;91(1):67-72. doi: 10.1002/jso.20280. PMID: 15999350

Recent systematic reviews

Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma: A Systematic Review and Meta-analysis.
Bogani G, Ditto A, Martinelli F, Lorusso D, Chiappa V, Donfrancesco C, Di Donato V, Indini A, Aletti G, Raspagliesi F
Int J Gynecol Cancer 2016 Feb;26(2):371-80. doi: 10.1097/IGC.0000000000000597. PMID: 26588238
CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis.
Gu P, Pan LL, Wu SQ, Sun L, Huang G
Eur J Radiol 2009 Jul;71(1):164-74. Epub 2008 Apr 18 doi: 10.1016/j.ejrad.2008.02.019. PMID: 18378417

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...